Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of a Melatonin Receptor Agonist to Prevent Migraine

This study has been terminated.
(Recruitment slow and administrative reasons)
Sponsor:
Collaborator:
Takeda
Information provided by (Responsible Party):
Swedish Medical Center
ClinicalTrials.gov Identifier:
NCT00739024
First received: August 19, 2008
Last updated: August 22, 2012
Last verified: August 2012
  Purpose

The purpose of this study is to see if ramelteon will reduce the number of migraine headaches over a 12 week period. The safety and tolerability of ramelteon will also be evaluated. Ramelteon has been approved by the U.S. Food and Drug Administration (FDA) for insomnia (trouble sleeping); however; ramelteon has not been approved for the prevention of migraines.


Condition Intervention Phase
Migraine
Migraine With Aura
Migraine Without Aura
Drug: Ramelteon
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine

Resource links provided by NLM:


Further study details as provided by Swedish Medical Center:

Primary Outcome Measures:
  • T-Test [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    It was planned to use a simple T-Test or ANoVa for data analysis. No Analysis was made due to insufficient recruitment. Planned primary efficacy variable was the percent reduction in the average monthly miqraine/probable migraine frequency from the baseline period to the entire double-blind treatment phase of the study.


Enrollment: 18
Study Start Date: April 2008
Study Completion Date: September 2010
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Active Treatment
Ramelteon once daily (double-blind assignment)
Drug: Ramelteon
8 mg tablet, oral, once daily
Other Name: Rozerem
Placebo Comparator: Placebo
Placebo tablet, once daily (double-blind assignment)
Drug: Placebo
Placebo tablet, oral, once daily

Detailed Description:

Sleep has played an important role in migraine. Younger migraine sufferers usually report relief of migraine after sleep. In older migraine sufferers migraine is sometimes triggered with sleep changes. Occurrence of migraine in the early morning is very common. Therefore in these individuals regulation of sleep may improve the frequency of migraine. Recent PET studies done during migraine demonstrated activation of hypothalamus during migraine. In light of this new data and the known action of ramelteon on the melatonin receptors it may theoretically provide an insight on a possible mechanism of action in migraine.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, ages 18 to 65 years, inclusive.
  • An established history of migraine, with or without aura and probable migraine, conforming to the revised IHS criteria (2004) for at least 1 year before screening, sufficient to establish the diagnosis.
  • To be randomized, during the prospective 4-week baseline period (approximately 28 days before Visit 2), subjects must have more than 4 migraine/probable migraine attacks per month (using the 24-hour rule).
  • Must have been less than 50 years of age at the time of initial migraine onset.
  • Must have no clinically significant and relevant abnormalities on physical or neurologic examinations
  • Must have completed a washout of all prophylactic medications for migraine before the start of the 4-week prospective baseline period (ie, 28 days before Visit 2, when randomization occurs).
  • Female subjects must be at least 1 of the following:
  • postmenopausal, or
  • surgically incapable of being children, or
  • practicing a highly effective method of birth control

Exclusion Criteria:

  • Most frequent type of headache does not meet the revised IHS diagnostic criteria for migraine with aura or without aura or probable migraine.
  • Pregnant or lactating women, or sexually active women of childbearing potential who are not using an appropriate method of contraception.
  • Failed adequate trials of prophylactic agents with demonstrated or possible efficacy in the prophylaxis of migraine. These agents include beta-blockers, tricyclic antidepressants, valproate, topiramate, and methysergide.
  • Unable to complete the diary in a timely and accurate manner after each migraine headache attacks, either independently or with assistance.
  • Overuse of analgesics or specific agents for abortive treatment of migraine attacks, which makes the investigator suspect medication overuse headache.
  • Receiving non-pharmacological prophylactic treatments such as acupuncture, chiropractic, or massage, if these were started less than 1 month before the screening visit (Day -28). These therapies may be continued if started before that time.
  • Currently abusing alcohol or other drugs.
  • Have a central nervous system neoplasm or infection, demyelinating disease, degenerative or progressive central nervous system disease, or active epilepsy.
  • History of serious systemic disease, including hepatic insufficiency, renal insufficiency, a malignant neoplasm, any disorder in which prognosis for survival is less than 3 months, or any disorder which in the judgment of the investigator will place the subject at excessive risk by participation in a controlled trial.
  • Have a significant psychiatric disorder, such as acute psychosis, schizophrenia, severe bipolar disorder, or severe unipolar mood disorder, of sufficient severity to preclude safe and effective participation of the subject in the study.
  • Require continued use of any of protocol-defined prohibited medications during the study
  • Have any recent or remote history of suicide attempt or ideation
  • Known or strongly suspected to be non-compliant in administering daily medications.
  • Received an experimental drug or used an experimental device within 30 days before the Screening Visit.
  • Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator
  • Any reason for which the investigator, upon her evaluation, feels that it is in the subject's best interest not to continue on in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00739024

Locations
United States, Washington
Swedish Pain and Headache Center
Seattle, Washington, United States, 98104
Sponsors and Collaborators
Swedish Medical Center
Takeda
Investigators
Principal Investigator: Sheena K Aurora, MD Swedish Medical Center
  More Information

No publications provided

Responsible Party: Swedish Medical Center
ClinicalTrials.gov Identifier: NCT00739024     History of Changes
Other Study ID Numbers: CRC 0690
Study First Received: August 19, 2008
Results First Received: July 22, 2011
Last Updated: August 22, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Swedish Medical Center:
Migraine
Headache

Additional relevant MeSH terms:
Migraine Disorders
Migraine with Aura
Migraine without Aura
Brain Diseases
Central Nervous System Diseases
Headache Disorders
Headache Disorders, Primary
Nervous System Diseases

ClinicalTrials.gov processed this record on November 25, 2014